Indivior Plc
Research Indivior Plc (INDV) on Bullrun: valuation model: 1.2% overvalued, market cap USD 4.24B, P/E 12.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerINDV
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal1.2% overvalued
- Market capUSD 4.24B
- P/E12.8
- Financial periodQ2 2026
- RevenueUSD 343.00M
- Net incomeUSD 122.00M
- Free cash flowUSD 222.00M
- Gross margin85.4%
Valuation Snapshot
Bullrun's latest valuation model marks Indivior Plc as 1.2% overvalued; latest market cap is USD 4.24B; P/E is 12.8.
Peer valuation comparison
Latest P/E is 12.78x versus a Healthcare sector median of 24.46x (47.8% below).
Latest P/E is 12.78x versus a United States median of 24.87x (48.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.24B | USD 210.00M | -USD 93.00M | 80.2% | 1.64 | USD 195.00M | USD 319.00M | -USD 98.00M |
| FY2024 | USD 1.19B | USD 7.00M | USD 7.00M | 80.6% | 0.05 | USD 319.00M | USD 333.00M | -USD 337.00M |
| FY2023 | USD 1.09B | -USD 126.00M | -USD 308.00M | 84.1% | -0.92 | USD 316.00M | USD 240.00M | -USD 184.00M |
| FY2022 | USD 901.00M | -USD 42.00M | -USD 9.00M | 83.1% | -0.3 | USD 774.00M | n/a | -USD 15.00M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.24B | 12.8 | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.49B | 21.6 | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.55B | 207.2 | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.08B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.97B | 18.9 | n/a | n/a |
| 2021 | 2021-12-31 | USD 484.68M | 2.6 | n/a | n/a |
About Indivior Plc
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Indivior Plc overvalued or undervalued?
Bullrun's valuation model currently marks Indivior Plc as 1.2% overvalued.
What is Indivior Plc's market cap?
Indivior Plc's market capitalization is USD 4.24B.
What is Indivior Plc's P/E ratio?
Indivior Plc's price-to-earnings (P/E) ratio is 12.8.
What does Indivior Plc do?
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.